Longitudinal growth in children is determined by endochondrial ossification at the growth plates of long bones and spinal growth. Whilst the assessment, monitoring and treatment of conditions which are responsive to growth hormone is well documented, conditions where children have an underlying bone disorder are more challenging. This paper will outline the important, common, primary bone conditions that impact growth, the assessment and effects that disordered growth has on the functional impact of the child. It will also summarise the latest drug therapies that are available and are currently in clinical trials, which impact the management of growth children with bone disorders.
27 - 29 Nov 2019
British Society for Paediatric Endocrinology and Diabetes